NCODA Logo
RealGiDo study results showed median time on treatment and time to progression of 18.7 and 20.8 months, respectively, were not impacted by dose modifications with Gilotrif® (afatinib) as first-line therapyGilotrif safety profile observed in real-world setting showed that there were no new safety signals
Ridgefield, Conn., May 31, 2018 – Boehringer Ingelheim today announced results from a retrospective, observational real-world study assessing the impact of dose adjustments of Gilotrif® (afatinib) on safety and efficacy in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC). The study showed that dose adjustment with Gilotrif helped improve patient tolerability while maintaining treatment efficacy and reduced the frequency and intensity of drug reactions. These findings, which were consistent with clinical trials, were published online by the American Society of Clinical Oncology (ASCO) n advance of its 2018 annual conference. Read article .